

Spiriva[®] HandiHaler[®] (tiotropium) – First-time generic

- On August 16, 2023, <u>Lupin launched</u> an <u>AB-rated</u> generic version of Boehringer Ingelheim's <u>Spiriva HandiHaler (tiotropium)</u> inhalation capsules.
 - Lupin was granted 180-days of generic exclusivity.
- Spiriva HandiHaler is approved for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Spiriva HandiHaler is indicated to reduce exacerbations in COPD patients.
- Tiotropium is also available as brand <u>Spiriva Respimat®</u> inhalation solution.
 - Spiriva Respimat carries the same indication as Spiriva HandiHaler and is also approved for long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older.
- According to IQVIA, Spiriva HandiHaler annual sales for the 12-month period ending in March 2023 were \$1.3 billion.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.